LANTHEUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Lantheus Holdings, Inc. on Behalf of Lantheus Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Lantheus Holdings, Inc. for possible violations of federal securities laws and unlawful business practices following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On August 6, 2025, Lantheus reported second quarter 2025 results with earnings-per-share (EPS) and revenue figures that missed market expectations [3]. - The company lowered its full year 2025 revenue guidance from $1.550 billion - $1.585 billion to $1.475 billion - $1.51 billion, and adjusted fully diluted EPS guidance from $6.60 - $6.70 per share to $5.50 - $5.70 per share [3]. - Consolidated net revenue for the second quarter was $378 million, a decrease of 4.1%, with sales from the radiopharmaceutical oncology product PYLARIFY contributing $250.6 million, down 8.3% [3]. Stock Market Reaction - Following the announcement of the disappointing results, Lantheus's stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [3].